Today: 10 April 2026
UnitedHealth stock slips into year-end close — what traders are watching next
31 December 2025
2 mins read

UnitedHealth stock slips into year-end close — what traders are watching next

NEW YORK, December 31, 2025, 17:12 ET — After-hours

  • UnitedHealth ended lower in late trade as U.S. health-care stocks also slipped.
  • Minnesota’s DHS is routing certain Medicaid claims through Optum for extra checks before payment.
  • Focus now shifts to UnitedHealth’s next results and 2026 outlook in late January.

UnitedHealth Group Inc shares were down $2.03, or 0.6%, at $330.11 in after-hours trading on Wednesday, after moving between $329.46 and $333.24 in the regular session. About 4.2 million shares changed hands.

The pullback matters because investors are entering 2026 focused on two levers that can swing health-insurer earnings quickly: medical-cost trends and the pace of regulatory scrutiny tied to government-funded programs.

UnitedHealth has been a bellwether for managed care. When sentiment shifts on Medicare and Medicaid oversight, the stock often trades less on day-to-day news and more on expectations for the next guidance reset.

The broader tape leaned risk-off into the close. The Health Care Select Sector SPDR Fund fell about 0.6% on the day and the SPDR S&P 500 ETF slid about 0.7%.

In Minnesota, the Department of Human Services has launched a pre-payment review process for fee-for-service Medicaid claims in 14 benefits and services it has identified as “high-risk,” with Optum overseeing the review. Pre-payment review means claims are vetted before money goes out, rather than being audited after payment. mn.gov // Minnesota’s State Portal

At a Monday media briefing, state Medicaid director John Connolly said the first claim cycle ended December 25 and that about 80,000 claims were sent to Optum for review, with the process expected to repeat roughly every two weeks. He said preliminary information was expected later this week. WDIO.com

For investors, the immediate financial impact is hard to size from the outside. The bigger signal is that states are tightening controls around Medicaid spending, a reminder that administrative changes can ripple through payment timing and compliance costs for firms that touch government health programs.

That backdrop adds to a separate cleanup effort underway inside UnitedHealth. In a letter disclosed earlier this month after external audits of its Optum units, CEO Stephen Hemsley said several action plans had already been completed and that “more than half will be finalized by the end of this year.” Reuters

UnitedHealth runs its insurance business under UnitedHealthcare and its services and analytics platform under Optum, which includes care delivery and a pharmacy benefit manager. Those operations make the company more diversified, but they also widen its exposure to policy shifts.

Traders are now looking ahead to the next catalyst: UnitedHealth said it will release full-year 2025 results and provide 2026 financial guidance on Tuesday, Jan. 27, before the market opens, with an 8 a.m. ET conference call. UnitedHealth Group

When that guidance arrives, investors typically zero in on the medical care ratio — the share of premium revenue spent on medical claims — because it’s a quick read on whether costs are running hot or normalizing. Medicare Advantage, the privately run version of Medicare, is especially sensitive to shifts in reimbursement and utilization.

U.S. equity markets will be closed on Jan. 1 for New Year’s Day and reopen on Jan. 2. Until UnitedHealth reports, investors are likely to keep trading the stock off the same themes: the pace of medical-cost normalization and any fresh policy or enforcement headlines tied to government health programs. nyse.com

Stock Market Today

  • DraftKings Stock Faces Uncertainty as 2026 Revenue Guidance Sparks Investor Caution
    April 9, 2026, 6:11 PM EDT. DraftKings (NASDAQ:DKNG) trades near $23.94, holding a 0.79% upside to the $24.13 price target by 24/7 Wall St. Despite strong Q4 revenue growth of 42.82% and first-ever full-year GAAP profit, shares dropped nearly 25% over the past year. The stock is caught between proven profitability and heavy investment in its new Predictions platform, which isn't yet included in 2026 revenue guidance of $6.5 billion to $6.9 billion, raising investor concerns. The CEO highlights Predictions as a major growth driver from a $10 billion market opportunity, with recent record volume spikes. Analysts remain mostly bullish, pushing consensus targets above $36, though risks include execution challenges and margin pressures from state tax rises.

Latest article

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts
Previous Story

INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026
Next Story

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Go toTop